marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-12-2024
Eton Pharmaceuticals Balance Sheet 2011-2024 | ETON
Annual Balance Sheet Eton Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-10.8 M | -7.73 M | -14.5 M | -7.51 M | -26.7 M | -13.2 M | - | - | - | - | - | - | |
Long Term Debt |
- | 5.38 M | 5.26 M | 6.76 M | 4.54 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
5.38 M | 1.03 M | 1.42 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 4.56 M | - | 520 K | - | - | - | - | - | - |
Total Current Liabilities |
16.2 M | 6.46 M | 4.56 M | 3.79 M | 1.96 M | 2.02 M | - | - | - | - | - | - | - |
Total Liabilities |
16.3 M | 12 M | 9.84 M | 10.7 M | 6.52 M | 2.02 M | 1.31 M | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-104 M | -103 M | -94.1 M | -92.2 M | -64.2 M | -45.9 M | -8.64 M | - | - | - | - | - | - |
Total Assets |
31.7 M | 25 M | 27.5 M | 26.3 M | 17.1 M | 28.3 M | 13.4 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
21.4 M | 16.3 M | 14.4 M | 21.3 M | 12.1 M | 26.7 M | 13.2 M | - | - | - | - | - | - |
Book Value |
15.5 M | 13.1 M | 17.6 M | 15.7 M | 10.6 M | 26.3 M | 12.1 M | - | - | - | - | - | - |
Total Shareholders Equity |
15.5 M | 13.1 M | 17.6 M | 15.7 M | 10.6 M | 26.3 M | -6.87 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Eton Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
126 K | 145 K | - | 22 K | 4.2 M | 4.55 M | 5.11 M | 5.38 M | 5.68 M | 5.99 M | 6.33 M | 5.26 M | 5.55 M | 5.86 M | 6.18 M | 6.53 M | 6.53 M | 6.53 M | 6.53 M | 4.54 M | 4.54 M | 4.54 M | 4.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
19.9 M | 18.4 M | 15.3 M | 16.3 M | 14.6 M | 14.2 M | 12.7 M | 12 M | 10.3 M | 9.8 M | 9.81 M | 9.84 M | 10.9 M | 9.17 M | 9.63 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 6.52 M | 6.52 M | 6.52 M | 6.52 M | 2.02 M | 2.02 M | 2.02 M | 2.02 M | 1.31 M | 1.31 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-107 M | -108 M | -105 M | -104 M | -102 M | -101 M | -106 M | -103 M | -104 M | -101 M | -99.4 M | -94.1 M | -95.2 M | -89.1 M | -87 M | -92.2 M | -92.2 M | -92.2 M | -92.2 M | -64.2 M | -64.2 M | -64.2 M | -64.2 M | -45.9 M | -45.9 M | -45.9 M | -45.9 M | -8.64 M | -8.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
35.8 M | 31.8 M | 30.8 M | 31.7 M | 31.5 M | 30.9 M | 23.9 M | 25 M | 21.5 M | 23 M | 23.2 M | 27.5 M | 26.6 M | 29.9 M | 31.2 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 28.3 M | 28.3 M | 28.3 M | 28.3 M | 13.4 M | 13.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
20.3 M | 17.7 M | 16.7 M | 21.4 M | 22.1 M | 21.6 M | 14.7 M | 16.3 M | 13.4 M | 17 M | 15.2 M | 14.4 M | 22.7 M | 25.8 M | 25.1 M | 21.3 M | 21.3 M | 21.3 M | 21.3 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 26.7 M | 26.7 M | 26.7 M | 26.7 M | 13.2 M | 13.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
16 M | 13.5 M | 15.5 M | 15.5 M | 16.9 M | 16.7 M | 11.2 M | 13.1 M | 11.2 M | 13.2 M | 13.4 M | 17.6 M | 15.7 M | 20.7 M | 21.6 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | 12.1 M | 12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
16 M | 13.5 M | 15.5 M | 15.5 M | 16.9 M | 16.7 M | 11.2 M | 13.1 M | 11.2 M | 13.2 M | 13.4 M | 17.6 M | 15.7 M | 20.7 M | 21.6 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | -6.87 M | -6.87 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency